Skip to main content
ADPT
NASDAQ Life Sciences

Officer Harlan Robins Files Intent to Sell $6.8M in Shares Following Recent Vesting

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$13.32
Mkt Cap
$2.051B
52W Low
$6.675
52W High
$20.76
52W Position info
100% above low
Off High info
36% below high
Rel. Volume info
1.5× avg
Market data snapshot near publication time

ADPT sits 100% above its 52-week low of $6.675.

Summary

An officer of Adaptive Biotechnologies Corp, Harlan S. Robins, has filed a Form 144 indicating an intent to sell 470,266 shares of common stock, valued at approximately $6.83 million.


Key Events · Ownership and Investor Activity · ADPT

  • Officer Files Intent to Sell

    Harlan S. Robins, an officer of Adaptive Biotechnologies Corp, has filed a Form 144 to sell 470,266 shares of common stock.

  • Substantial Value

    The proposed sale has an approximate market value of $6,828,262.32, representing a significant transaction.

  • Shares from Vesting Awards

    The securities to be sold were acquired upon the vesting of restricted stock units and performance stock units on March 4, 2026.

  • Follows Recent Sales

    This intent to sell follows previous sales by Mr. Robins in early March 2026, totaling 77,021 shares for gross proceeds of $1,355,892.14 over the past three months.


Analysis · ADPT · Life Sciences

This Form 144 indicates a significant intent to sell shares by Harlan S. Robins, an officer of Adaptive Biotechnologies Corp. The proposed sale of approximately $6.83 million in common stock represents a notable transaction for a company of this size. While the shares were acquired through the vesting of restricted and performance stock units, the substantial value and the filer's executive role make this a material event. This filing also follows a pattern of recent sales by Mr. Robins, suggesting ongoing liquidity or portfolio rebalancing. Investors should monitor the actual execution of these sales and consider the potential impact of this insider activity on market sentiment.

At the time of this filing, ADPT was trading at $13.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $6.68 to $20.76. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ADPT - Latest Insights

ADPT
Jul 01, 2026, 4:35 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $22.76
Real-time Price: $22.24 info
Change: -$0.5268 (-2%) info
Market Cap: $3.564B info
ADPT
Jun 22, 2026, 4:07 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $17.37
Real-time Price: $22.24 info
Change: +$4.87 (+28%) info
Market Cap: $3.564B info
ADPT
Jun 17, 2026, 6:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $17.13
Real-time Price: $22.24 info
Change: +$5.11 (+30%) info
Market Cap: $3.564B info
ADPT
Jun 15, 2026, 4:50 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $16.50
Real-time Price: $22.24 info
Change: +$5.74 (+35%) info
Market Cap: $3.564B info
ADPT
Jun 15, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $15.97
Real-time Price: $22.24 info
Change: +$6.27 (+39%) info
Market Cap: $3.564B info